Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620230 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00620230 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 46 participants.
The verdict
NCT00620230, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
Interventions
- DRUG NVP-VAK694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620230
The ClinicalTrials.gov registry entry for NCT00620230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NVP-VAK694 is the first listed.
NCT00620230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620230 about?
NCT00620230 is a clinical study titled "Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects". This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
What is the current status of trial NCT00620230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00620230?
The interventions under investigation include: NVP-VAK694 (DRUG).
Who is sponsoring clinical trial NCT00620230?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.